SEARCH

SEARCH BY CITATION

References

  • 1
    Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 14451449.
  • 2
    Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996; 110: 12381243.
  • 3
    Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metast Rev 1992; 11: 179195.
  • 4
    Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107: 35653577.
  • 5
    Merritt AJ, Potten CS, Watson AJM, Loh DY, Nakayama K, Nakayama K, Hickman JA. Differential expression of bcl-2 in intestinal epithelia: correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci 1995; 108: 22612271.
  • 6
    Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G, Viale G. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and ade-nocarcinomas. Hum Pathol 1995; 26: 534540.
  • 7
    Walker NI, Winterford CM, Williamson RM, Kerr JF. Ethionine-induced atrophy of rat pancreas involves apoptosis of acinar cells. Pancreas 1993; 8: 443449.
  • 8
    Nishino H, Muroi T, Hoashi S, Tomita H, Sekimoto T, Yamada H, Ootsuka I, et al. The influence of the alcohol and the low protein diet on rat pancreas. J Gastroenterol 1994; 91: 12201227.
  • 9
    Columbano A, Ledda-Columbano GM, Rajalakshmi S, Sarma DSR. Occurrence of cell death (apoptosis) in preneoplastic and neoplastic liver cells. A sequential study. Am J Pathol 1984; 116: 441446.
  • 10
    Bursch W, Lauer B, Timmermann-Trosiener I, Barther G, Schuppler J, Schulte-Hermann R. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters. Carcinogenesis 1984; 5: 453458.
  • 11
    Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor β1. Cancer Res 1992; 52: 385388.
  • 12
    Fukuda K, Kojiro M, Chiu J-F. Induction of apoptosis by transforming growth factor-β1 in the rat hepatoma cell line McA-RH7777: a possible association with tissue transglutaminase expression. Hepatology 1993; 18: 945953.
  • 13
    Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber R, Schlicht H, Huang S. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 15411554.
  • 14
    Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasa-hara A, Fusamoto H, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 13541359.
  • 15
    Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, Fusamoto H, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468474.
  • 16
    Mochizuki K, Hayashi N, Hiramatsu N, Katayama K, Kawanishi Y, Kasahara A, Fusamoto H, et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996; 24: 17.
  • 17
    Benedetti A, Brunelli E, Risicate R, Cilluffo T, Jezequel A-M, Orlandi F. Subcellular changes and apoptosis induced by ethanol in rat liver. J Hepatol 1988; 6: 137143.
  • 18
    Goldin RD, Hunt NC, Clark J, Wickramasinghe SN. Apoptotic bodies in a murine model of alcoholic liver disease: reversibility of ethanol-induced changes. J Pathol 1993; 171: 7376.
  • 19
    Ledda-Columbano GM, Coni P, Faa G, Manenti G, Columbano A. Rapid induction of apoptosis in rat liver by cycloheximide. Am J Pathol 1992; 140: 545549.
  • 20
    Kerr J. Definition of apoptosis and overview of its incidence. In: LanvinM, WattersD, eds. Programmed cell death: the cellular and molecular biology of apoptosis. Chur, Switzerland: Harwood Academic Publishers, 1993: 115.
  • 21
    Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest 1994; 94: 21832192.
  • 22
    Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493501.
  • 23
    Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995; 21: 14651468.
  • 24
    Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 14401443.
  • 25
    Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of the bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 1986; 83: 52145218.
  • 26
    Alnemri ES, Fernendes TF, Haldar S, Croce CM, Litwack G. Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B-leukemias. Cancer 1992; 52: 491495.
  • 27
    Martinou JC, Dubois-Dauohin M, Staple JK, Rodriguez I, Frankowski H, Missotten M, Albertini P, et al. Overexpression of bcl-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994; 13: 10171030.
  • 28
    Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteu A, et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 1996; 2: 8086.
  • 29
    Charlotte F, L'Hermine, Martin N, Geleyn Y, Nollet M, Gaulard P, Zafrani ES. Immunohistochemical detection of bcl–2 protein in normal and pathological human liver. Am J Pathol 1994; 144: 460465.
  • 30
    Kurosawa H, Que FG, Kuntz SM, LaRusso NF, Gores GJ. Hepatocytes in the bile duct ligated rat express Bcl-2: an adaptive mechanism to inhibit apoptosis by toxic bile salts. Gastroenterology 1996; 110: A1244.
  • 31
    Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is urso-deoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 2: 834836.
  • 32
    Lindor KD, Dickson ER, Baldus WP, Jorgenson RA, Ludwig J, Murtaugh PA, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 12841290.
  • 33
    Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 13421347.
  • 34
    Heathcote EJ, Cauch-Duder K, Walker V, Bailey RJ, Blendis LM, Ghent CM, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of Ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 11491156.
  • 35
    Scheuer PJ. Liver biopsy interpretation. Ed 3. London: Bailliere Tindall, 1980.
  • 36
    De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, et al. A classification of chronic hepatitis. Lancet 1968; ii: 626628.
  • 37
    Hsu S, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 1981; 29: 577580.
  • 38
    Rappaport AM, Borowy ZJ, Longheed WM, Lotto WN. Subdivision of hexagonal liver lobules into a structural and functional unit. Anat Rec 1954; 119: 1133.
  • 39
    Nakanuma Y, Ohta G, Kono N, Kobayashi K, Kato Y. Electron microscopic observation of destruction of biliary epithelium in primary biliary cirrhosis. Liver 1983; 3: 238248.
  • 40
    Bianchi L. Necroinflammatory liver diseases. Semin Liver Dis 1986; 6: 185198.
  • 41
    Ashkenas J, Werb Z. Proteolysis and the biochemistry of life-or-death decisions. J Exp Med 1996; 183: 19471951.
  • 42
    Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology 1995; 21: 17251741.
  • 43
    Bhathal PS, Gall JAM. Deletion of hyperplastic biliary epithelial cells by apoptosis following removal of the proliferative stimulus. Liver 1985; 5: 311325.
  • 44
    Ferrari C, Penna A, Giuberti T, Tong MJ, Ribera E, Fiaccadori F, Chisari FV. Intrahepatic nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol 1987; 139: 20502655.
  • 45
    Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert CA, Palmiter RD, Brinster RL, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248: 361364.
  • 46
    Koziel MJ, Dudley D, Afdhal N, Choo QL, Houghton M, Ralston R, Walker BD. Hepatitis C virus-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 75227532.
  • 47
    Kita H, Moriyama T, Kaneko T, Harase I, Nomura M, Miura H, Nakamura I, et al. HLA B44–restricted cytotoxic T lymphocytes recognizing an epitope in hepatitis C virus nucleocapsid protein. Hepatology 1993; 18: 10391044.
  • 48
    Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A, Tsuneyama K, et al. Hepatitic bile duct injuries in chronic hepatitis C: histopathologic and immunohistochemical studies. Mod Pathol 1994; 7: 937945.
  • 49
    Jones AL, Hradek GT, Renston RH, Wong KY, Karlaganis G, Paumgartner G. Autoradiographic evidence for hepatic lobular concentration gradient of bile acid derivative. Am J Physiol 1980; 238: 233237.
  • 50
    Groothuis GM, Hardonk MJ, Keulemans KP, Nieuwenhuis P, Meijer DK. Autoradiographic and kinetic demonstration of acinar heterogeneity of taurocholate transport. Am J Physiol 1982; 243: 455462.
  • 51
    Ballardini G, Mirakian R, Bianchi F, Pisi E, Doniach D, Bottazzo G. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984; 3: 10091013.
  • 52
    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of Ursodeoxycholic acid. Hepatology 1990; 11: 1215.
  • 53
    Tanaka H, Makino Y, Miura T, Hirano F, Okamoto K, Komura K, Sato Y, et al. Ligand-independent activation of the glucocorticoid receptor by Ursodeoxycholic acid: repression of IFN-γ-induced MHC class II gene expression via glucocorticoid receptor-dependent pathway. J Immunol 1996; 156: 16011608.
  • 54
    Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, et al. Immunomodulatory effects of Ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358364.
  • 55
    Calmus Y, Guechot J, Podevin P, Bonnefis MT, Giboudeau J, Poupon R. Differential effects of chenodeoxycholic and Ursodeoxycholic acids on interleukin-1, interleukin-6, and tumor necrosis factor-a production by monocytes. Hepatology 1992; 16: 719723.
  • 56
    Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology 1991; 14: 920926.
  • 57
    Bolta R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther 1995; 272: 930938.
  • 58
    Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterisation of patients with a complete biochemical response to Ursodeoxycholic acid. Gut 1995; 36: 935938.